Resource Summary Report

Generated by NIF on Sep 16, 2026

COLO 205

RRID:CVCL_0218
Type: Cell Line

Proper Citation

RRID:CVCL_0218

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0218

Proper Citation: RRID:CVCL_0218

Description: Cell line COLO 205 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Colon adenocarcinoma

Defining Citation: PMID:565251, PMID:2041050, PMID:3335022, PMID:3629545, PMID:6277475, PMID:7651727, PMID:9023415, PMID:9294210, PMID:9331090, PMID:10051639, PMID:10674020, PMID:10700174, PMID:10737795, PMID:11414198, PMID:12068308, PMID:12584437, PMID:15748285, PMID:17088437, PMID:19372543, PMID:20164919, PMID:20215515, PMID:20570890, PMID:22068913, PMID:22347499, PMID:22384151, PMID:22460905, PMID:22628656, PMID:23272949, PMID:23631600, PMID:23856246, PMID:23933261, PMID:24279929, PMID:24670534, PMID:24755471, PMID:25485619, PMID:25841592, PMID:25877200, PMID:25926053, PMID:25944804, PMID:25984343, PMID:26537799, PMID:26589293, PMID:27377824, PMID:27397505, PMID:27807467, PMID:28192450, PMID:28196595, PMID:28683746, PMID:28854368, PMID:29718670, PMID:30894373, PMID:30971826, PMID:31068700, PMID:31733513, PMID:31978347, PMID:35839778, PMID:38861359

Comments: Population: Caucasian., Part of: NCI-7 clinical proteomics reference material cell line panel., Part of: NCI-60 cancer cell line panel., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Part of: AstraZeneca Colorectal cell line (AZCL) panel.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: COLO 205

Synonyms: Colo 205, CoLo 205, COLO-205, Colo-205, COLO.205, Colo205, COLO205, Co 205, Colorado 205

Cross References: BTO:BTO_0000179, CLO:CLO_0002544, CLO:CLO_0050630, EFO:EFO_0003082, MCCL:MCC:0000107, CLDB:cl826, CLDB:cl5096, AddexBio:C0009018/4908, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-3610, ATCC:CCL-222, BCRC:60054, BioGRID_ORCS_Cell_line:846, BioSample:SAMN03470991, BioSample:SAMN10987610, cancercelllines:CVCL_0218, CCRID:1101HUM-PUMC000132, CCRID:3101HUMTCHu102, Cell_Model_Passport:SIDM00826, ChEMBL-Cells:CHEMBL3308348, ChEMBL-Targets:CHEMBL614561, CLS:300380, ColonAtlas:COLO205, Cosmic:685865, Cosmic:720342, Cosmic:738936, Cosmic:875901, Cosmic:876711, Cosmic:887242, Cosmic:889524, Cosmic:897456, Cosmic:902796, Cosmic:905961, Cosmic:948130, Cosmic:948823, Cosmic:974244, Cosmic:995391, Cosmic:1043806, Cosmic:1044256, Cosmic:1045404, Cosmic:1066207, Cosmic:1067224, Cosmic:1092596, Cosmic:1132577, Cosmic:1154651, Cosmic:1175838, Cosmic:1184101, Cosmic:1187303, Cosmic:1223135, Cosmic:1305351, Cosmic:1310944, Cosmic:1312336, Cosmic:1374634, Cosmic:1479612, Cosmic:1609485, Cosmic:1676745, Cosmic:1708401, Cosmic:1945864, Cosmic:1995368, Cosmic:1998438, Cosmic:2036651, Cosmic:2301968, Cosmic:2560250, Cosmic:2651868, Cosmic:2800580, Cosmic-CLP:905961, DepMap:ACH-001039, ECACC:87061208, EGA:EGAS00001000610, EGA:EGAS00001000978, FCS-free:180-2-342-3-16-3, GDSC:905961, GEO:GSM2089, GEO:GSM50186, GEO:GSM50250, GEO:GSM206459, GEO:GSM274717, GEO:GSM274718, GEO:GSM274728, GEO:GSM741249, GEO:GSM743441, GEO:GSM750794, GEO:GSM799329, GEO:GSM799392, GEO:GSM827422, GEO:GSM843490, GEO:GSM846289, GEO:GSM886940, GEO:GSM888007, GEO:GSM1153400, GEO:GSM1178029, GEO:GSM1178030, GEO:GSM1178031, GEO:GSM1181248, GEO:GSM1181264, GEO:GSM1346867, GEO:GSM1374451, GEO:GSM1374452, GEO:GSM1448172, GEO:GSM1669683, GEO:GSM2124638, GEO:GSM2549994, IARC_TP53:21116, ICLC:HTL00010, KCB:KCB 200719YJ, KCLB:10222, LINCS_LDP:LCL-1173, Lonza:253, MetaboLights:MTBLS227, NCI-DTP:COLO 205, PharmacoDB:COLO205_221_2019, PRIDE:PXD001550, PRIDE:PXD003539, PRIDE:PXD005235, PRIDE:PXD005940, PRIDE:PXD005942, PRIDE:PXD005946, PRIDE:PXD030304, Progenetix:CVCL_0218, PubChem_Cell_line:CVCL_0218, RCB:RCB2127, SKY/M-FISH/CGH:2801, TKG:TKG 0457, Wikidata:Q54814074

ID: CVCL_0218

Record Creation Time: 20220427T215514+0000

Record Last Update: 20260913T002418+0000

Ratings and Alerts

No rating or validation information has been found for COLO 205.

No alerts have been found for COLO 205.

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 231 mentions in open access literature.

Listed below are recent publications. The full list is available at NIF .

Zhang W, et al. (2026) A poly(I:C)/QS-21-based in situ vaccine synergizes with anti-PD-1 therapy to overcome tumor immunoresistance. Cell reports. Medicine, 102932.

Jia A, et al. (2026) Dual targeting of SLC25A51 and succinate dehydrogenase selectively depletes mitochondrial NAD+ to eradicate KRAS-driven AML. Cell metabolism, 38(6), 1113.

Sritharan S, et al. (2026) Secretion of IL-6 and TGF-??2 by Colon Cancer Cells May Promote Resistance to Chemotherapy. Indian journal of clinical biochemistry : IJCB, 41(2), 259.

Cong K, et al. (2026) A comprehensive review of anti-colorectal cancer alkaloids from traditional Chinese medicine: Sources, chemical structures, mechanisms and therapeutic applications. British journal of pharmacology.

Chen H, et al. (2026) CCL3 and IL-7 Synergistically Enhance CAR-T Efficacy in Solid Tumors. Advanced science (Weinheim, Baden-Wurttemberg, Germany), e75993.

Ghaffari S, et al. (2026) A fully human pan VL9 HLA-E TCRm antibody enables functional dissection of HLA-E biology and checkpoint signaling. iScience, 29(5), 115669.

Jothimani G, et al. (2025) Unraveling the mechanism of microRNA-134 in colon cancer progression: Targeting KRAS and PIK3CA for cell cycle control and histone deacetylase regulation. Experimental cell research, 444(2), 114385.

Abrantes R, et al. (2025) Pan-carcinoma sialyl-Tn-targeting expands CAR therapy to solid tumors. Cell reports. Medicine, 6(9), 102350.

Martinez-Martinez D, et al. (2025) Chemotherapy modulation by a cancer-associated microbiota metabolite. Cell systems, 16(9), 101397.

Baglamis S, et al. (2025) Clonal dispersal is associated with tumor heterogeneity and poor prognosis in colorectal cancer. iScience, 28(5), 112403.

Enciso-Martinez A, et al. (2025) Targeting Oncofoetal Chondroitin Sulphate Allows Identification of Tumour-Derived Extracellular Vesicles. Journal of extracellular vesicles, 14(6), e70106.

Castro J, et al. (2025) A Potent, Selective, Small-Molecule Inhibitor of DHX9 Abrogates Proliferation of Microsatellite Instable Cancers with Deficient Mismatch Repair. Cancer research, 85(4), 758.

Ortiz-Ruiz MJ, et al. (2025) Mediator Kinase Inhibitor Selectivity and Activity in Colorectal Cancer. ACS chemical biology, 20(7), 1792.

Lee HM, et al. (2024) Epigenome Reprogramming Through H3K27 and H3K4 Trimethylation as a Resistance Mechanism to DNA Methylation Inhibition in BRAFV600E-Mutated Colorectal Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 30(22), 5166.

Eisenberg V, et al. (2024) Targeting Tumor-Associated Sialic Acids Using Chimeric Switch Receptors Based on Siglec-9 Enhances the Antitumor Efficacy of Engineered T Cells. Cancer immunology research, 12(10), 1380.

Kunkel MW, et al. (2024) HTS384 NCI60: The Next Phase of the NCI60 Screen. Cancer research, 84(15), 2403.

Xie B, et al. (2024) Strengthening E-cadherin adhesion via antibody-mediated binding stabilization. Structure (London, England : 1993), 32(2), 217.

Gunji D, et al. (2024) Longitudinal phosphoproteomics reveals the PI3K-PAK1 axis as a potential target for recurrent colorectal liver metastases. Cell reports, 43(12), 115061.

Li Y, et al. (2024) IGSF8 is an innate immune checkpoint and cancer immunotherapy target. Cell, 187(11), 2703.

Wei W, et al. (2023) FBXW7?? loss-of-function enhances FASN-mediated lipogenesis and promotes colorectal cancer growth. Signal transduction and targeted therapy, 8(1), 187.